The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

@article{Pitt1999TheEO,
  title={The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.},
  author={B. Pitt and F. Zannad and W. Remme and R. Cody and A. Castaigne and A. Perez and J. Palensky and J. Wittes},
  journal={The New England journal of medicine},
  year={1999},
  volume={341 10},
  pages={
          709-17
        }
}
BACKGROUND AND METHODS Aldosterone is important in the pathophysiology of heart failure. In a doubleblind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was… Expand
Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms
TLDR
Administration of spironolactone reduced the composite of death and cardiovascular hospitalization in patients with NYHA classes I to II HF, suggesting that spironOLactone could be beneficial when administered on top of optimal therapy among patients with HF and mild or no symptoms. Expand
Effectiveness and safety of spironolactone for systolic heart failure.
TLDR
The findings suggest that the benefits of spironolactone in clinical practice may be reduced compared with other guideline-recommended medications. Expand
The effect of spironolactone use on heart failure mortality: a population-based study.
TLDR
Although spironolactone use was not associated with improved long-term survival in the general HF population, it was associated withImproved long- term survival in patients enrolled in HF clinics, highlighting the challenges of knowledge translation from a clinical trial into practice. Expand
Spironolactone for heart failure with preserved ejection fraction.
TLDR
In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. Expand
A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
TLDR
Treatment with 50 mg spironolactone did not change left ventricular mass index, cardiac function, or blood pressure in hemodialysis patients, and there was no difference in the secondary outcomes of mean 24-hour systolic or diastolic ambulatory blood pressure,left ventricular ejection fraction, 6-minute walk test distance, or New York Heart Association functional class. Expand
Effect of carvedilol on survival in severe chronic heart failure.
TLDR
The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial. Expand
Spironolactone in patients with heart failure and preserved ejection fraction.
TLDR
For patients with HFPEF, the administration of spironolactone was associated with an increase in all-cause readmission, perhaps due to the higher rate of hyperpotassemia. Expand
Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
TLDR
There were considerable effects of age on increased rates of adverse safety outcomes and these results should be weighed when considering spironolactone for older heart failure with preserved ejection fraction patients. Expand
Usefulness of spironolactone in a specialized heart failure clinic.
TLDR
Although the complication rate was higher, the benefits of spironolactone seen in RALES extended to participants not in a trial who were treated with similar doses and followed closely in a clinic specializing in heart failure. Expand
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
TLDR
Codesartan was generally well tolerated and significantly reduced cardiovascular deaths and hospital admissions for heart failure and there was no significant heterogeneity for candesartan results across the component trials. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
The effect of digoxin on mortality and morbidity in patients with heart failure.
TLDR
Digoxin did not reduce overall mortality, but it reduced the rate of hospitalization both overall and for worsening heart failure, which defines more precisely the role of digoxin in the management of chronic heart failure. Expand
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
TLDR
The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions. Expand
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
TLDR
Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor. Expand
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
TLDR
Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients. Expand
Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.
TLDR
There is a pronounced but variable neurohormonal activation in heart failure even in patients with similar clinical findings, and the effect of enalapril on mortality is related to hormonal activation in general and the renin-angiotensin system in particular. Expand
Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
TLDR
The addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms, and the effect seems to be due to a reduction in death from progression of heart failure. Expand
Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
  • B. Pitt
  • Medicine
  • The American journal of cardiology
  • 1996
TLDR
Daily doses of 12.5 to 25 mg of spironolactone coadministered with conventional therapy of ACE inhibitors, loop diuretics, and digitalis are relatively safe (provided that serum potassium levels are monitored) and effective in blocking the effects of aldosterone, while reducing the potential for hypokalemia in patients with heart failure. Expand
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
TLDR
The principal finding is that cardiac norepinephrine uptake as assessed by 123I-metaiodobenzylguanidine scintigraphy increased with spironolactone, which is a good result for patients with New York Heart Association II to III congestive heart failure. Expand
Efficacy and tolerance of spironolactone in essential hypertension.
TLDR
It is concluded that spironolactone administered in daily practice reduced BP without inducing adverse metabolic adverse effects and that in patients with essential hypertension, doses should be kept below 100 mg. Expand
Captopril in heart failure. A double blind controlled trial.
TLDR
Captopril seemed to be of considerable value in the long term treatment of severe cardiac failure in a double blind trial. Expand
...
1
2
3
4
5
...